Development of nanosensors can distinguish viral from bacterial pathogens

Significance 

Many different types of bacteria and viruses can cause pneumonia, but there is no easy way to determine which microbe is causing a particular patient’s illness. Difficulty in recognizing viruses from bacteria makes it harder for doctors to choose effective treatments because the antibiotics commonly used to treat bacterial pneumonia won’t help patients with viral pneumonia. In addition, limiting the use of antibiotics is an important step toward curbing antibiotic resistance.

The challenge is that there are a lot of different pathogens that can lead to different kinds of pneumonia and even with the most extensive and advanced testing, the specific pathogen causing someone’s disease can’t be identified in about half of patients. Moreover, if viral pneumonia is treated with antibiotics, then we risk antibiotic resistance, which is a big problem, with no improvement in patient health condition

In a new study MIT researchers led by Sangeeta Bhatia, the John and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science at MIT and a member of MIT’s Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science, showed that their newly sensors could accurately distinguish bacterial and viral pneumonia within two hours, using a simple urine test to read the results. The research work is now published in the Journal Proceedings of the National Academy of Sciences

One reason why it has been difficult to distinguish between viral and bacterial pneumonia is that there are so many microbes that can cause pneumonia, including the bacteria Streptococcus pneumoniae and Haemophilus influenzae, and viruses such as influenza and respiratory syncytial virus. In designing their sensor, the research team decided to focus on measuring the host’s response to infection, rather than trying to detect the pathogen itself. Viral and bacterial infections provoke distinctive types of immune responses, which include the activation of enzymes called proteases, which break down proteins. The MIT team found that the pattern of activity of those enzymes can serve as a signature of bacterial or viral infection.

The human genome encodes more than 500 proteases, and many of these are used by cells that respond to infection, including T cells, neutrophils, and natural killer (NK) cells. The authors collected 33 publicly available datasets of genes that are expressed during respiratory infections. By analyzing those data, they were able to identify 39 proteases that appear to respond differently to different types of infection.

The authors then used those data to create 20 different sensors that can interact with those proteases. The sensors consist of nanoparticles coated with peptides that can be cleaved by particular proteases. Each peptide is labeled with a reporter molecule that is freed when the peptides are cleaved by proteases that are upregulated in infection. Those reporters are eventually excreted in the urine. The urine can then be analyzed with mass spectrometry to determine which proteases are most active in the lungs. The researchers tested their sensors in five different mouse models of pneumonia, caused by infections of Streptococcus pneumoniaeKlebsiella pneumoniaeHaemophilus influenzae, influenza virus, and pneumonia virus of mice. After reading out the results from the urine tests, the researchers used machine learning to analyze the data. Using this approach, they were able to train algorithms that could differentiate between pneumonia versus healthy controls, and also distinguish whether an infection was viral or bacterial, based on those 20 sensors.

The researchers also found that their sensors could distinguish between the five pathogens they tested, but with lower accuracy than the test to distinguish between viruses and bacteria. One possibility the researchers may pursue is developing algorithms that can not only distinguish bacterial from viral infections, but also identify the class of microbes causing a bacterial infection,  which could help doctors choose the best antibiotic to combat that type of bacteria.

The urine-based readout is also amenable to future detection with a paper strip, similar to a pregnancy test, which would allow for point-of-care diagnosis. To this end, the researchers identified a subset of five sensors that could put at-home testing closer within reach. However, more work is needed to determine if the reduced panel would work similarly well in humans, who have more genetic and clinical variability than mice.

In their study, the researchers also observed that bacterial infections, proteases secreted by neutrophils were more prominently seen, which was expected because neutrophils tend to respond more to bacterial infections than viral infections. On contrast, viral infections, on the other hand, provoked protease  activity from T cells and NK cells, which usually respond more to viral infections. One of the sensors that generated the strongest signal was linked to a protease called granzyme B, which triggers programmed cell death. The researchers found that this sensor was highly activated in the lungs of mice with viral infections, and that both NK and T cells were involved in the response.

In summary, MIT researchers have now designed a sensor that can distinguish between viral and bacterial infections, which they hope will help doctors to choose the appropriate treatment. For clinical translation, the researchers are now now developing versions for human use that could be administered using either a nebulizer or an inhaler similar to an asthma inhaler. Another useful platform to detect the results using a breathalyzer instead of a urine test, which could give results even more quickly.

Development of nanosensors can distinguish viral from bacterial pathogens - Advances in Engineering

About the author

Sangeeta N. Bhatia, MD, PhD

John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science

Massachusetts Institute of Technology

Sangeeta Bhatia earned her BS at Brown University, followed by an MS in mechanical engineering at MIT, a PhD in biomedical engineering at the Harvard-MIT Division of Health Sciences and Technology, and an MD at Harvard Medical School.

Bhatia’s multidisciplinary team develops tools for use in diagnostics and detection, and in precision therapeutics to specifically target tumors. Nanosensors designed by the Bhatia team are capable of detecting and profiling very early-stage tumors, and can be analyzed via a simple urine test. The same technology may also yield insights into a tumor’s response to certain therapies. The Bhatia Lab has also created human microlivers, which model human drug metabolism, liver disease, and interaction with pathogens.

Reference

Anahtar M, Chan LW, Ko H, Rao A, Soleimany AP, Khatri P, Bhatia SN. Host protease activity classifies pneumonia etiology. Proc Natl Acad Sci U S A. 2022;119(25):e2121778119. doi: 10.1073/pnas.2121778119.

Go To Proc Natl Acad Sci U S A.

Check Also

Dynamically Reconfigurable Bipolar Optical Gradient Force Induced by Mid-Infrared Graphene Plasmonic Tweezers for Sorting Dispersive Nanoscale Objects - Advances in Engineering

Dynamically Reconfigurable Bipolar Optical Gradient Force Induced by Mid-Infrared Graphene Plasmonic Tweezers for Sorting Dispersive Nanoscale Objects